Live Breaking News & Updates on Stoke Therapeutic

Stay updated with breaking news from Stoke therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $14.00 at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK – Free Report) had its target price decreased by Cantor Fitzgerald from $18.00 to $14.00 in a research note released on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2023 earnings at ($2.42) EPS and FY2024 earnings at […] ....

United States , Barry Ticho , Jonathan Allan , Stoke Therapeutics Inc , Metlife Investment Management , Needham Company , Stoke Therapeutics Company Profile , Canaccord Genuity Group , Cantor Fitzgerald , Securities Exchange Commission , York Mellon Corp , Jpmorgan Chase Co , Swiss National Bank , Stoke Therapeutics , Free Report , Stoke Therapeutic , Genuity Group , Moderate Buy , Get Free Report , General Counsel Jonathan Allan , Exchange Commission , National Bank , New York Mellon Corp , Life Investment Management , Rhumbline Advisers , Stoke Therapeutics Daily ,